Table of Contents  
AUTHORS REPLY
Year : 2014  |  Volume : 16  |  Issue : 3  |  Page : 414

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial


1 Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, USA
2 Southwest Oncology Group Statistical Center and Fred Hutchinson Cancer Research Center, Seattle, USA

Date of Web Publication07-Mar-2014

Correspondence Address:
Ian M Thompson
Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1008-682X.125714

Rights and Permissions

How to cite this article:
Thompson IM, Tangen CM, Goodman PJ. Re: Long-term survival of participants in the Prostate Cancer Prevention Trial. Asian J Androl 2014;16:414

How to cite this URL:
Thompson IM, Tangen CM, Goodman PJ. Re: Long-term survival of participants in the Prostate Cancer Prevention Trial. Asian J Androl [serial online] 2014 [cited 2019 Oct 18];16:414. Available from: http://www.ajandrology.com/text.asp?2014/16/3/414/125714 - DOI: 10.4103/1008-682X.125714

We appreciate the opportunity to comment on Dr. Silberstein and Sartor's commentary on our recent update of the Prostate Cancer Prevention Trial.[1]

We are disappointed that the authors did not reflect on perhaps the greatest challenge to prostate cancer in the USA today: the severe risk of overdetection and overtreatment. Indeed, this risk is so compelling that it led the US Preventive Services Task Force to recommend against prostate-specific anitgen testing. Data are clear that in our effort to detect cancers that we know we can help, we find orders of magnitude more cancers that we simply do not help. Even for the small fraction of men who are not treated but are managed with active surveillance, the data are clear: it costs as much as surgery and the repeated clinic visits and biopsies adversely affect their quality of life and place them at medical risk.

One perspective of 5-alpha reductase inhibitor-based prevention is in the context of an overall early detection strategy. This class of agents reduces detection (and treatment) of inconsequential tumors, while preserving and enhancing detection of aggressive tumors that benefit from detection. We suggest that this information be provided to men who have opted for prostate-specific antigen screening; it can then be the privilege of the individual patient to perform the risk-benefit assessment for himself rather than the physician's priorities dictating whether cancer prevention is appropriate.

We continue to seek improved methods to identify the individual who is most likely to benefit from the use of these agents.



 
  References Top

1.Silberstein JL, Sartor O. Long-term survival of participants in the prostate cancer: prevention trial. Asian J Androl. 2014. doi: 10.4103/1008-682X.122868. [Epub ahead of print].  Back to cited text no. 1
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed1189    
    Printed42    
    Emailed0    
    PDF Downloaded241    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]